Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20979
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZolota, V.en
dc.contributor.authorBatistatou, A.en
dc.contributor.authorTsamandas, A. C.en
dc.contributor.authorIliopoulos, G.en
dc.contributor.authorScopa, C. D.en
dc.contributor.authorBonikos, D. S.en
dc.date.accessioned2015-11-24T19:11:55Z-
dc.date.available2015-11-24T19:11:55Z-
dc.identifier.issn1537-3649-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20979-
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*genetics/*physiopathologyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectCyclin-Dependent Kinase Inhibitor p21en
dc.subjectCyclins/*biosynthesisen
dc.subjectFemaleen
dc.subject*Gene Expression Regulation, Neoplasticen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectKi-67 Antigen/*biosynthesisen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeovascularization, Pathologic/*geneticsen
dc.subjectStomach Neoplasms/*genetics/*physiopathologyen
dc.subjectTransforming Growth Factor beta/*biosynthesisen
dc.subjectTransforming Growth Factor beta1en
dc.subjectTumor Suppressor Protein p53/*biosynthesisen
dc.titleImmunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1385/IJGC:32:2-3:83-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12794244-
heal.identifier.secondaryhttp://www.springerlink.com/content/43v76k4108710622/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2002-
heal.abstractBACKGROUND: Transforming growth factors-beta (TGF-betas) are multifunctional polypeptides with crucial role as regulators of cellular growth and differentiation. It has been reported that TGF-beta1 plays a biphasic action on tumorigenesis thus inducing or inhibiting malignant properties of the epithelial cells. METHODS: TGF-beta1 expression was analyzed in 56 patients with gastric carcinoma by immunohistochemical methods and compared with the expression of p21, p53, and Ki67, as well as with angiogenesis. The correlation of these markers with clinicopathological parameters was also evaluated. RESULTS: TGF-beta1 expression was detected in 71% of tumors and was more frequent in adenocarcinomas of the intestinal type (p < 0.001). Positivity of p21WAF1, and p53 was observed in 32% and 51% of the tumors, respectively. A high Ki67 proliferating index was detected in 53.5% of the tumors. TGF-beta1 expression was significantly correlated with p21 expression (p < 0.001) and was inversely correlated with microvessel density. p21 expression was also higher in tumors with low proliferating index (p < 0.01). There was no apparent correlation between the expression of these markers and tumor stage, depth of invasion, or lymphnode metastases. CONCLUSION: The findings show that TGF-beta1 may be involved in the activation of the cdk inhibitor p21WAF1 in gastric adenocarcinomas, suggesting p53-independent induction of p21 in gastric cells. TGF-beta1 does not seem to contribute to the alteration of the angiogenic status of these tumors.en
heal.journalNameInt J Gastrointest Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Zolota-2002-Immunohistochemical.pdf238.24 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons